BofA Securities Analyst Adjusts ProQR Therapeutics Price Target
BofA Securities analyst Alec Stranahan has maintained a 'Buy' rating on ProQR Therapeutics while lowering the price target from $8 to $7.
Stocks · News reference
ProQR Therapeutics announced that it will present new clinical and preclinical data for its RNA editing candidates AX-0810 and AX-0811 at several upcoming scientific conferences.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BofA Securities analyst Alec Stranahan has maintained a 'Buy' rating on ProQR Therapeutics while lowering the price target from $8 to $7.
ProQR Therapeutics announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of €12.447 million and providing updates on its clinical pipeline.
ProQR Therapeutics announced upcoming presentations of its Axiomer RNA editing platform at major conferences including TIDES Europe, AASLD The Liver Meeting 2026, and Nature Conferences RNA at the Bench and Bedside V. The company will showcase clinical data from its Phase 1 AX-0810 study demonstrating favorable safety and target engagement, as well as preclinical data for next-generation candidate AX-0811, with initial Phase 1 data expected in early January 2027.